VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 367 filers reported holding VANECK VECTORS ETF TR in Q3 2016. The put-call ratio across all filers is 1.03 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $48,016 | -26.0% | 1,785 | -17.2% | 0.00% | 0.0% |
| Q2 2023 | $64,884 | -6.9% | 2,155 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $69,691 | +4.1% | 2,155 | -7.8% | 0.00% | 0.0% |
| Q4 2022 | $66,954 | -15.2% | 2,337 | -28.5% | 0.00% | -50.0% |
| Q3 2022 | $79,000 | -11.2% | 3,267 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $89,000 | -85.7% | 3,267 | -79.9% | 0.00% | -81.8% |
| Q1 2022 | $624,000 | +743.2% | 16,267 | +605.1% | 0.01% | +1000.0% |
| Q4 2021 | $74,000 | +8.8% | 2,307 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $68,000 | -9.3% | 2,307 | +4.5% | 0.00% | 0.0% |
| Q2 2021 | $75,000 | -13.8% | 2,207 | -17.5% | 0.00% | -50.0% |
| Q1 2021 | $87,000 | -10.3% | 2,675 | -1.1% | 0.00% | 0.0% |
| Q4 2020 | $97,000 | +438.9% | 2,705 | +478.0% | 0.00% | – |
| Q3 2020 | $18,000 | -75.3% | 468 | -83.0% | 0.00% | -100.0% |
| Q3 2016 | $73,000 | -3.9% | 2,745 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $76,000 | – | 2,745 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 738,500 | $20,220,000 | 66.82% |
| Baymount Management LP | 145,000 | $3,970,000 | 28.08% |
| New Harbor Financial Group, LLC | 1,371,341 | $37,547,000 | 18.51% |
| New Harbor Financial Group, LLC | 1,291,700 | $35,366,000 | 17.44% |
| MKP Capital Management, L.L.C. | 1,500,000 | $41,070,000 | 13.74% |
| Windmill Hill Asset Management Ltd | 844,600 | $23,125,000 | 11.94% |
| Hollow Brook Wealth Management LLC | 768,567 | $21,043,000 | 11.57% |
| Grand Central Investment Group | 261,915 | $7,171,000 | 10.33% |
| Point72 Europe (London) LLP | 1,467,000 | $40,166,000 | 8.50% |
| Slate Path Capital LP | 4,600,000 | $125,948,000 | 7.87% |